Clinical Trial Update: Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial in advanced hepatocellular carcinoma involving bavituximab, axitinib, and avelumab has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Axitinib (Axitinib)
• Bavituximab (bavituximab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-05-03